

S 1128

Preserving Access to Orphan Drugs Act of 2013

Congress: 113 (2013–2015, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Jun 11, 2013

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Jun 11, 2013)

Official Text: <https://www.congress.gov/bill/113th-congress/senate-bill/1128>

Sponsor

Name: Sen. Toomey, Patrick [R-PA]

Party: Republican • **State:** PA • **Chamber:** Senate

Cosponsors (6 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Casey, Robert P., Jr. [D-PA]	D · PA		Jun 11, 2013
Sen. Crapo, Mike [R-ID]	R · ID		Jun 11, 2013
Sen. Carper, Thomas R. [D-DE]	D · DE		Jul 23, 2013
Sen. Wicker, Roger F. [R-MS]	R · MS		Jul 24, 2013
Sen. Rubio, Marco [R-FL]	R · FL		Jan 8, 2014
Sen. Murphy, Christopher [D-CT]	D · CT		Jun 26, 2014

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Jun 11, 2013

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
113 HR 2315	Identical bill	Jul 25, 2013: Rereferred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Summary (as of Jun 11, 2013)

Preserving Access to Orphan Drugs Act of 2013 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions (orphan drug) from the annual fee on manufacturers or importers with branded prescription drug sales exceeding \$5 million.

Makes this Act effective as if included in PPACA.

Actions Timeline

- **Jun 11, 2013:** Introduced in Senate
- **Jun 11, 2013:** Read twice and referred to the Committee on Finance.